First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure−activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2005-11, Vol.48 (22), p.6779-6782
Hauptverfasser: Linton, Steven D, Aja, Teresa, Armstrong, Robert A, Bai, Xu, Chen, Long-Shiuh, Chen, Ning, Ching, Brett, Contreras, Patricia, Diaz, Jose-Luis, Fisher, Craig D, Fritz, Lawrence C, Gladstone, Patricia, Groessl, Todd, Gu, Xin, Herrmann, Julia, Hirakawa, Brad P, Hoglen, Niel C, Jahangiri, Kathy G, Kalish, Vincent J, Karanewsky, Donald S, Kodandapani, Lalitha, Krebs, Joseph, McQuiston, Jeff, Meduna, Steven P, Nalley, Kip, Robinson, Edward D, Sayers, Robert O, Sebring, Kristen, Spada, Alfred P, Ternansky, Robert J, Tomaselli, Kevin J, Ullman, Brett R, Valentino, Karen L, Weeks, Suzanne, Winn, David, Wu, Joe C, Yeo, Pauline, Zhang, Cheng-zhi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure−activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm050307e